Puma Biotechnology Inc stock is traded at $8.03, with a volume of 105,663. It is down -17.86% in the last 24 hours and down -15.53% over the past month. Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Previous Close:
$9.77
Open:
$8.27
24h Volume:
105,663
Relative Volume:
0.27
Market Cap:
$414.25M
Revenue:
$227.18M
Net Income/Loss:
$24.38M
P/E Ratio:
16.81
EPS:
$0.4774
Net Cash Flow:
$53.60M
1W Performance:
-23.13%
1M Performance:
-15.53%
6M Performance:
+7.72%
1Y Performance:
+63.78%
1-Day Range:
$7.59$8.65
1-Week Range:
$7.59$10.88
52-Week Range:
$4.58$11.50
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology IncSector
HealthcareIndustry
BiotechnologyPhone
(424) 248-6500Address
10880 WILSHIRE BLVD., LOS ANGELES, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS